- 16Volume 3, 2020Sep 08, Issue 18Aug 25, Issue 17Jul 14, Issue 14Jun 30, Issue 13Jun 16, Issue 12Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
A rewarding initiative born from visionary Mary Stutts! Thank you to our interns & our leaders @Agenus_Bio Berkeley for building the next generation of innovators & disruptors. Great coverage @abc7newsbayarea! twitter.com/jbuell01/statu…
$AGEN is proud to partner with visionary Mary Stutts & TCEL, empowering youth through virtual internships driven by our CMO Al Dadson. Great success! https://t.co/TFERswWTKg via @abc7newsbayarea @Agenus_Bio
— Jennifer Buell (@jbuell01) September 24, 2020
$AGEN newsletter is now available: Balstilimab Monotherapy and Balstilimab plus Zalifrelimab Trials Presented at ESMO: agenusbio.com/wp-content/upl… #ESMO20 #oncology #immunotherapy #cervicalcancer
Replay of discussion of $AGEN #ESMO20 data presentation hosted by @Phipps_MC @WilliamBlair with Dr. O'Malley @OSUCCC_James is now available and can be accessed here: williamblair.zoom.us/rec/play/B24AG… #oncology #immunotherapy #cervicalcancer twitter.com/Agenus_Bio/sta…
Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #ESMO20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: https://t.co/1QtBwTAjKc #oncology pic.twitter.com/v8dNHkNnjT
— Agenus Inc. ($AGEN) (@Agenus_Bio) September 21, 2020
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab #fightcancer #ESMO20 @Agenus_Bio twitter.com/morgan_buell/s…
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab #fightcancer #ESMO20 @Agenus_Bio https://t.co/XR9STg9vNZ
— Morgan Buell Gallion (@morgan_buell) September 22, 2020
WATCH NOW: the inaugural episode of "18 Minutes with..." @MediaJerNYC @sciam and $AGEN President & COO, Dr. Jennifer Buell (@jbuell01). Learn about disruptive approaches to #cancer, #COVID19, & #Immunotherapy twitter.com/MediaJerNYC/st…
Here is the inaugural episode of "18 Minutes With...", featuring Dr. Jennifer Buell of @Agenus_Bio
— Jeremy Abbate (@MediaJerNYC) September 18, 2020
Cancer, COVID-19 and Access to Combination Therapies https://t.co/vsPXmhLh0t via @sciam
@beilis_jay Only registered attendees can listen to the conference live. A replay of the conference can be accessed at the $AGEN website at investor.agenusbio.com/events-and-pre…
Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #ESMO20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: investor.agenusbio.com/news-releases/… #oncology
Excellent presentation by @lillian_siu on MK-4830, a first-in-class, ILT4 targeting antibody discovered @Agenus_Bio and partnered with @Merck. Siu described how MK-4830 reprograms tumour-associated macrophages, relieving myelosuppression & enhancing T cell activity. twitter.com/myESMO/status/… Retweeted by Agenus Inc. ($AGEN)
Excited for patients with cervical cancer! Potential new therapy: onclive.com/view/balstilim… @OncLive @Agenus_Bio @garo_armen @jbuell01 @barbara_ryan12 #balstilimab #PD1 #cervicalcancer #ESMO2020 Retweeted by Agenus Inc. ($AGEN)
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status. #ESMO20 twitter.com/TargetedOnc/st…
In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status.https://t.co/XqszdYffHT #gyncsm #ESMO20
— Targeted Oncology (@TargetedOnc) September 21, 2020
Highlights of data featured in $AGEN #ESMO20 presentation. View full video on $AGEN website: agenusbio.com/balstilimab-ba… #oncology #immunotherapy
Cervical cancer claims the lives of more then 4500 young women each year; @Agenus_Bio is committed to change this current reality. #CervicalCancer #Immunotherapy #ESMO20 twitter.com/JohnNosta/stat…
BREAKING! In metastatic cervical #cancer, Agenus advances efficacy with their complementary CTL4 and PD1 combo—27% response vs monotherapy 14% with #keytruda. @agenus_bio @jbuell01 #oncology #ESMO2020 pic.twitter.com/VmuwDsJLBe
— John Nosta (@JohnNosta) September 18, 2020
BREAKING! In metastatic cervical #cancer, Agenus advances efficacy with their complementary CTL4 and PD1 combo—27% response vs monotherapy 14% with #keytruda. @agenus_bio @jbuell01 #oncology #ESMO2020 Retweeted by Agenus Inc. ($AGEN)
$AGEN bal +/- zal at #ESMO show ORR of 19 & 27% in PD-L1 (+); PD-L1 (-) responders & favorable safety with treatment-related d/c 3.7 & 6.5% investor.agenusbio.com/news-releases/…
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer investor.agenusbio.com/news-releases/…
$AGEN's presentation is one of the many affected by this delay twitter.com/myESMO/status/…
#ESMO20: We are currently experiencing a technical delay in the uploading of presentations for some Mini Oral sessions. We are working hard to fix this issue as quickly as possible so please bear with us. Many apologies for the inconvenience. https://t.co/tHIjnWO406 pic.twitter.com/V4M8pfi60R
— ESMO - Eur. Oncology (@myESMO) September 18, 2020
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO investor.agenusbio.com/news-releases/…
Watch @jbuell01's full interview with @sciam here: buff.ly/3hJRW2a #immunotherapy #COVID__19 #18MinutesWith
$AGEN's late-breaking ESMO abstract has been released and can be viewed here under Gynaecological cancers 2: cslide.ctimeetingtech.com/esmo2020/atten…. The countdown to $AGEN's ESMO presentation begins! #ESMO2020 #oncology #immunotherapy
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With investor.agenusbio.com/news-releases/…